Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paule Chinet-Charrot
Observed names:
P Charrot-Chinet,
P Chinet-Charrot,
P. CHINET-CHARROT,
P. Chinet,
P. Chinet-Charrot
Institution:
Centre Henri Becquerel
Observed institutions:
Hôpital Charles-Nicolle,
Centre Léon Bérard,
Centre François Baclesse,
Institut Claudius Regaud,
Institut Bergonié,
Centre Henri Becquerel
show all 6
OpenAlex ID:
A5041283530
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
2015
·
Karim Fizazi
, Laura Faivre
, et al.
·
The Lancet Oncology
·
238
Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients)
1995
·
R. Rozan
, E. Albuisson
, et al.
·
Radiotherapy and Oncology
·
117
Scleroderma-like cutaneous lesions induced by paclitaxel: A case study
2003
·
I. Kupfer
, X. Balguerie
, et al.
·
Journal of the American Academy of Dermatology
·
77
Non-Hodgkin’s lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres
2001
·
J.-L. Lagrange
, A. Ramaioli
, et al.
·
Annals of Oncology
·
73
A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial
2011
·
Karim Fizazi
, Francois Lesaunier
, et al.
·
European Journal of Cancer
·
53
PDF
Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study
2009
·
Florence Joly
, Nadine Houédé
, et al.
·
Clinical Genitourinary Cancer
·
48
A Multicenter Phase II Study with Triptorelin (Sustained-Release LHRH Agonist) in Advanced or Recurrent Endometrial Carcinoma: A French Anticancer Federation Study
1999
·
C. Lhommé
, P. Vennin
, et al.
·
Gynecologic Oncology
·
47
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer
2001
·
M Namer
, P Soler-Michel
, et al.
·
European Journal of Cancer
·
28
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
·
F. Joly
, J.F. Héron
, et al.
·
Gynecologic Oncology
·
25
Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study
2004
·
F. Joly
, N. Tchen
, et al.
·
Journal of Clinical Oncology
·
12
[Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer].
1996
·
J Chauvergne
, P Chinet-Charrot
, et al.
·
PubMed
·
9
Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer
2006
·
F. JOLY
, H. BOURGEOIS
, et al.
·
International Journal of Gynecological Cancer
·
6
[Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide].
1993
·
J Chauvergne
, J F Héron
, et al.
·
PubMed
·
5
Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial
2017
·
S. Oudard
, I. Latorzeff
, et al.
·
Annals of Oncology
·
3
Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): A phase II GINECO trial
2008
·
E. Kurtz
, D. Besson
, et al.
·
Journal of Clinical Oncology
·
3
Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial
2005
·
P. Chinet-Charrot
, F. Joly
, et al.
·
Journal of Clinical Oncology
·
1
Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) based chemotherapy
2002
·
A. Chevalier
, P. Fumoleau
, et al.
·
1
[Neo-adjuvant (or preliminary) chemotherapy in cancer of the bladder. Evaluation].
1992
·
P Charrot-Chinet
·
PubMed
·
1
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12
2026
·
Cécile Vicier
, Farah Erdogan
, et al.
·
European Journal of Cancer
Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
2023
·
Valentina Orlando
, Damien Drubay
, et al.
·
Clinical Genitourinary Cancer
PDF
Show more works
View as search
Works count:
20
Citation count:
747
H-index:
10
I10-index:
10
Year
Topic
Type
